Sandoz Can't Get New Trial After $39M Eyelash Serum IP Loss
By Craig Clough · September 22, 2023, 5:54 PM EDT
A Colorado federal judge denied a new trial bid by Novartis' generic-drug making arm Sandoz over a patent covering a drug to grow eyelashes after a jury awarded $39 million to...
To view the full article, register now.